Skip to main content
NewslettersWatchlist

Elevation Oncology Inc(ELEV-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

PR Newswire - Wed Apr 26, 2023

NEW YORK, April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that an abstract featuring SYSA1801 (EO-3021) Phase 1 clinical data has been selected for a poster presentation and poster discussion at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, IL. The ongoing Phase 1 dose escalation and dose expansion study is evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors and is being conducted in China by Elevation Oncology's partner, CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093). Elevation Oncology remains on track to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 in the second half of 2023.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

investor newsletter
A look at how people are using the best all-around investing product. Plus, top stock picks from our new Readers’ Portfolio
ETF or Exchange Traded Fund text on black block
market news
The close: Month-end repositioning spurs late-day stock rally
Trader Anthony Confusione works on the floor of the New York Stock Exchange, Thursday, May 30.
alternative investments
Why this money manager thinks investors should get off the sidelines but still be defensive
Illustration of Chris Kerlow for The Mover. June 23/24, 2023. Illustration by Joel Kimmel
globe advisor weekly newsletter
Canadian investors are ‘underserved’ in alternative investments and private capital
Investors want greater clarity from their advisors around what RI means and how it can fit their portfolios.
alternative investments
Why rising interest in traditional fixed income is not affecting alternatives
A man looks up as he leans a red ladder against a tall stack of coins that is topped with an interest rate symbol.
alternative investments
Fund houses buy up ‘alts’ specialists to move beyond equities and bonds
FILE PHOTO: Larry Fink, Chief Executive Officer of BlackRock, takes part in the Yahoo Finance All Markets Summit in New York, U.S., February 8, 2017. REUTERS/Lucas Jackson
opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza
alternative investments
Four ways to create more diversified and resilient portfolios
One of a set. Graphic Arrow on abstract background.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).